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Abstract
Background: There are only few cases of renal pathology induced by Lyme borreliosis in the literature, as this
damage is rare and uncommon in humans. This patient is the first case of minimal change glomerular disease
associated with chronic Lyme borreliosis.
Case presentation: A 65-year-old Caucasian woman was admitted for an acute edematous syndrome related to
a nephrotic syndrome. Clinical examination revealed violaceous skin lesions of the right calf and the gluteal region
that occurred 2 years ago. Serological tests were positive for Lyme borreliosis and skin biopsy revealed lesions of
chronic atrophic acrodermatitis. Renal biopsy showed minimal change glomerular disease. The skin lesions and
the nephrotic syndrome resolved with a sequential treatment with first ceftriaxone and then corticosteroids.
Conclusion: We report here the first case of minimal change disease associated with Lyme borreliosis. The
pathogenesis of minimal change disease in the setting of Lyme disease is discussed but the association of Lyme
and minimal change disease may imply a synergistic effect of phenotypic and bacterial factors. Regression of
proteinuria after a sequential treatment with ceftriaxone and corticosteroids seems to strengthen this conceivable
association.
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Background
Lyme disease-associated nephritis is rare in humans.
The majority of reported cases are related to membrano-
proliferative glomerulonephritis (MPGN) caused by
renal deposition of immune-complexes [1–4]. We report
here a unique case of minimal change disease (MCD)
associated with chronic Lyme borreliosis that resolved




A 65-year-old woman was admitted for an acute edema-
tous syndrome associated with asthenia. The patient had
a past medical history of hypertension, dyslipidemia,
bilateral gonarthrosis and left coxarthrosis. On admis-
sion, physical examination revealed arterial hypertension
(163/89 mmHg) without fever and a violaceous cutane-
ous rash of the right leg that had appeared 2 years
before. It had started as a small painful round macule of
the foot that progressively extended to the whole calf
and the gluteal region (Fig. 1). Neurological examination
revealed painful peripheral neuropathy on the right leg.
Electrocardiogram was normal.
Laboratory data showed hypoalbuminemia (1,2 g/dl)
associated with severe proteinuria (7,03 g/24 h) and a
recent decrease of renal function (serum creatinin level
increase from 0,84 to 1,3 mg/dl). Urinalysis showed
cytolipiduria without hematuria or pyuria (11/mm3 and
22/mm3, respectively). Serological tests for viral infections
(HBV, HCV, EBV, HIV), antinuclear and antineutrophil
cytoplasmic antibodies were negative. Complement was
normal. Cryoglobulin (monoclonal IgM-kappa and poly-
clonal IgG) was found. Serum protein electrophoresis
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revealed an oligoclonal increase of two IgG-lambda and
one IgM-lambda condensations.
Histological examination of the skin biopsy showed a
diffuse, rather dense dermal infiltration reaching the
subcutaneous adipose tissue. It consisted predominantly
of CD3+/CD5+ T-lymphocytes, admixed with numerous
CD79a+/CD138+ polyclonal plasma cells (expressing in
comparable amounts kappa and lambda light chains)
and fewer CD20+ B-cells suggestive with chronic atro-
phic acrodermatitis (Fig. 2).
Serological tests for Lyme disease confirmed the
diagnosis of chronic borreliosis: the enzyme-linked
Fig. 1 Clinical features of chronic atrophic acrodermatitis. Lesions started from the back of the foot and spread to the inguinal and gluteal
regions. Areas of uninvolved skin areas are present between the lesions
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Fig. 2 Biopsies features. Skin biopsy: a Scanning magnification (X25): a patchy perivascular and periadnexal cell infiltrate is present in the dermis
(HES stain). b Medium-power magnification (X100): a mononuclear cell infiltrate is present in the deep dermis around dilated vessels and sweat
glands (HES stain). c High-power magnification (X250): a dense lymphoplasmocytic perivascular infiltrate is present in the deep dermis (HES stain).
Renal biopsy: d Optical microscopy (X200): normal glomerulus with no segmental lesion (PAS stain). e1 Transmission electron microscopy (X8000):
podocyte effacement without deposits or double contour (Uranyl acetate and lead citrate stain). e2 Transmission electron microscopy (X20000):
podocyte effacement without deposits or double contour (Uranyl acetate and lead citrate stain)
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immunosorbent assay was positive for IgG (titer > 200
U/mL, normal value < 6) and IgM (Enzygnost® Lyme
link VLsE/IgG and Borreliosis/IgM used on the
BEPIII® system, Siemens Healthcare Diagnostic Products
GmbH, Marburg, Germany), and was confirmed by
immunoblotting. After further questioning, the patient
recalled a tick-bite 9 years before on this leg, but neither
migratory erythema nor arthritis.
A renal biopsy disclosed chronic vascular lesions and
normal glomeruli devoid of immune deposits (Fig. 2).
Transmission electron microscopy showed a diffuse
podocyte effacement without any evidence of deposits
(Fig. 2). Specific polymerase chain reaction (PCR) by
LightMix Kit for the detection of Borrelia spp. (TIB
MOLBIOL, ROCHE, Berlin, Germany) performed on
DNA extracted from both skin and kidney biopsies was
negative.
A whole-body scan showed no evidence of lymphoma.
Renal ultrasound and doppler examinations were nor-
mal. The patient was not taking any medication that
could induce the MCD.
Evolution with treatment
Proteinuria slightly decreased after administration of
an angiotensin-converting enzyme inhibitor (ACEi) at
d8. After serological confirmation of Lyme borreliosis,
ceftriaxone was initiated (2 g/day by subcutaneous in-
jections starting on day 21 after diagnosis, d21). One
week later (i.e. on d28), corticosteroids (CS) were
added (70 mg prednisolone, i.e. 1 mg/kg). To prevent
an infection flare, CS administration was delayed.
At d24, i.e. 72 h after initiation of ceftriaxone ther-
apy, proteinuria decreased again (3.96 vs 7.03 before
treatment and vs 5.96 g/24 h after ACEi introduction)
and hypertension and the edematous syndrome im-
proved. At d48, the first antibiotherapy course was
discontinued. At d52, proteinuria was insignificant
(0.11 g/day) and CS were rapidly tapered (by 2.5 mg/
week). At d115, while CS dosage was 47.5 mg, pro-
teinuria was still insignificant (0.03 g/day) but the
neuropathic pain of the right foot persisted. Ele-
ctroneuromyographic and lumbosacral remnography
remained normal. Ceftriaxone therapy was again
started in association with pregabalin until d147 and
resulted in complete regression of the leg lesions and
pain. At d178, with 17.5 mg of CS, proteinuria remained
insignificant (0,29 g/day) and CS were further tapered
(2.5 mg every 15 days until 10 mg and then 1 mg every
month). At d245, with 9 mg CS, there was a complete
remission of the nephrotic syndrome (Fig. 3). CS were
totally stopped at d350 and after a 3-years follow-up,
proteinuria remained insignificant.
Fig. 3 Evolution of biologic and clinical parameters in response of therapeutic interventions. Left vertical axis: log scale. d0: diagnosis. d8: ACEi
introduction. d21: Ceftriaxone introduction. d28: Corticosteroid (CS) introduction. d46: end of ceftriaxone therapy. d52: Start of the CS Tapering,
2.5 mg per week. d115: ceftriaxone re-introduction, CS 47.5 mg. d147: end of second ceftriaxone therapy. d178: CS 17.5 mg/day, tapering of
2.5 mg/15 days until 10 mg then 1 mg every month. d245: CS 9 mg. Note : conversion factor units : Serum creatinine in mg/dL to μmol/L x 88,4
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Serological tests after 6 months and a 3-years
follow-up were still positive for IgG and became nega-
tive for IgM.
Discussion
Lyme disease is a tick-borne infection caused by Borrelia
burgdorferi, and can present with various clinical mani-
festations due to the ability of spirochetes to affect many
tissues [5]. Our patient seems to be the first case of
MCD associated with Lyme disease. This calls for several
comments.
Borrelia burgdorferi is known to induce Lyme nephritis
especially in dogs. In most cases, pathological findings are
membranoproliferative glomerulonephritis (MPGN) with
Lyme-specific antigen-antibody complex deposition on the
basal glomerular membrane [6–8]. In humans, we found
four MPGN [1–4] one crescentic and IgA-deposit nephrop-
athy [2] and a membranous nephropathy [9] in the setting
of Lyme disease.
Lyme disease-associated nephropathy is rare and its
pathogenesis still unclear. Role of immunomodulatory
phenomena such as the deposition of immune complexes
mediated by Lyme infection can be involved [6–8]. Bacter-
ial lipopolysaccharides (LPS) can favor the development of
MCD via disorganization of the podocyte cytoskeleton.
This phenomenon is explained by the upregulation of B7-
1, a costimulating factor responsible for glomerular per-
meability, induced by LPS biding with toll-like receptor 4
(TLR4) [10]. Interestingly, in Lyme disease, there is an up-
regulation of the expression of B7-1 and B7-2 [11]. Some
lipoproteins present on the surface of the bacteria can
bind and activate TLR 1, 2 and 4 [12]. Therefore, MCD in
our case may be due to a strong upregulation in podocytes
of B7-1 after the binding of lipoprotein from the surface
of the bacteria with TLR4.
The decrease of proteinuria after ceftriaxone therapy
observed in our case suggests a link between MCD and
Lyme disease. As described above, T-cells, podocytes
and bacterial wall antigens could be involved. Neverthe-
less, this phenomenon has not been so far described in
other cases of chronic Lyme disease and despite ceftriax-
one, CS, ACEi and low-sodium diet prescribed during
the hospitalization may themselves explain a decrease of
the proteinuria [13].
The co-existence of cryoglobulin and oligoclonal pro-
liferation of immunoglobulins on plasma electrophoresis
in the setting of MCD rendered important the exclusion
of a lymphoma. However, the results of the initial
workup were reassuring, and 3-years follow-up did not
disclose any evidence for it. Furthermore, drug-associated
MCD was excluded only with questioning, so that an
omission cannot be excluded definitely.
On the other hand, the diagnostic value of PCR in
Lyme disease remains unclear as it is used mainly for
research [5]. Besides, PCR was also negative in another
case report [1], and was not mentioned in other studies
[2–4, 9]. Moreover, in dogs, immunohistochemistry
assay did not show any evidence of renal invasion of
Borrelia in kidney tissues in dogs with suspected Lyme
nephritis [8], as well as results of PCR assays were only
positive for one biopsy on 4 dogs with a positive or
equivocal status for Lyme borreliosis [6].
Concerning treatment, our strategy introduced an
unsolved question: was ceftriaxone alone able to treat
MCD in our case? Besides ceftriaxone, the patient was
also treated by corticosteroids, the reference treatment
for MCD. Moreover, we added ACEi that had an effect
on the decrease of the proteinuria. This association
allowed a complete remission of MCD (negative protein-
uria at d52 and after a 3-years follow up). In previous
studies about infection-related MPGN treatment, anti-
biotics were first started, corticosteroids delayed and
then tapered [14]. Successful treatment resulted from
the synergistic effect of antibiotics on bacterial inoculum
and steroids on immune system.
Conclusion
Renal damage is rare in human Lyme disease and mostly
corresponds to MGPN. We reported here the first case
of MCD associated with Lyme disease. The involvement
of podocytes, T-cell mediated immune response and
bacterial wall antigens can be considered. It can be
speculated that some idiopathic MCD cases may be due
to latent Lyme (or other infectious diseases) involving
T-cell proliferation and podocyte dysfunction. The
association of Lyme disease and MCD implies a syn-
ergistic effect of phenotypic and bacterial factors.
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